Navigation Links
Amgen's Denosumab and Eli Lilly's Forteo/Forsteo Will Drive Robust Annual Growth in the Osteoporosis Drug Market From 2013 to 2018
Date:6/1/2009

Denosumab and Forteo/Forsteo Will Each Achieve Blockbuster Status in 2018, According to a New Report from Decision Resources

WALTHAM, Mass., June 1 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Amgen's novel agent denosumab and Eli Lilly's parathyroid hormone (PTH) analogue Forteo/Forsteo (teriparatide) will drive robust 4.3 percent annual growth in the osteoporosis drug market from 2013 to 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Osteoporosis finds that concerns about the long-term safety of bisphosphonates -- which currently dominate the market -- will help convince primary care physicians and specialists to switch patients to PTH analogues and novel agents such as denosumab. The uptake of denosumab, which has a convenient dosage regimen of bi-annual subcutaneous injections, will drive the agent to achieve blockbuster sales of $2 billion in 2018 for the treatment of osteoporosis and osteopenia. The report also forecasts that Forteo/Forsteo will achieve blockbuster status in 2018 with sales of approximately $2 billion. Forteo/Forsteo's uptake will be achieved as a result of its efficacy in reducing the frequency of fractures as well as the prevalent safety concerns about the bisphosphonates.

The report also finds that that the launches of third-generation selective estrogen receptor modulators (SERMs), most notably Eli Lilly's arzoxifene, will drive market growth. Physicians will increasingly prescribe these agents, particularly if they demonstrate significant efficacy in reducing nonvertebral fractures.

"Interviewed experts indicate that arzoxifene is the most promising of the third-generation SERMs, as they believe it may be as efficacious as Pfizer's Fablyn without increasing mortality," said Decision Resources Analyst Jeremy Goldman, M.D. "If Phase III clinical trial data confirms this, we forecast that arzoxifene will become the market-leading SERM, generating sales of $600 million in 2018."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                     Decision Resources, Inc.
    Christopher Comfort                    Elizabeth Marshall
    781-296-2597                           781-296-2563
    ccomfort@dresources.com                emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Virus Could Help Drive Obesity
2. Back to School Means Return of School Blood Drives
3. Expanding Prevalent Population Will Drive Dramatic Growth for the Asthma Drug Market in China
4. End-to-End HR Performance Benchmarks: Metrics That Will Help Turn the HR Cost Center into a Productivity Driver
5. Customized virus kills brain tumor stem cells that drive lethal cancer
6. National Survey Shows Employee Fears About Consumer-Driven Health Plans on Decline
7. Cancer stem cell subpopulation drives metastasis of human pancreatic cancer
8. Brain Defect Helps Drive Fragile X Syndrome
9. Moffitt Selects Microsofts Azyxxi to Help Drive Personalized Cancer Treatment
10. Genentech/Roches Lucentis and Eli Lillys Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets
11. Disabilities Rising Among Workers; Need for Employer-Driven Disability Awareness, Support Efforts Also Increases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work to improve their ... The patient is doing more than filling out a survey; in many cases health ... increasing emphasis in health care and research on the importance of active engagement with ...
(Date:10/13/2017)... IL (PRWEB) , ... October 13, 2017 , ... ... which established the certification process to promote standards of excellence for the field ... Symposium, scheduled for March 22 – 25, 2018 in Orlando, Florida at the ...
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of ... ElderCounsel, a national organization of elder law and special needs planning attorneys. “Membership in ... It also provides a forum to network with elder law attorneys nationwide,” said Somekh. ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association ... Featuring a collection of specialty vendors and unique items from across the nation, this ... health and wellness services offered by the VNA. The boutique will be open ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... 2017   West Pharmaceutical Services, Inc. (NYSE: ... drug administration, today shared the results of a study ... the intradermal administration of polio vaccines. The study results ... May 2017 by Dr. Ondrej Mach , Clinical ... Organization (WHO), and recently published in the journal ...
(Date:10/5/2017)... Oct. 5, 2017  In response to the ... and Maxillofacial Surgeons (AAOMS) released prescribing recommendations that ... be used as a first-line therapy to manage ... Recognizing the value and ... Paper "Opioid Prescribing: Acute and Postoperative Pain Management" ...
(Date:10/4/2017)... to the Centers for Disease Control and Prevention (CDC), influenza vaccination ... is helping communities across Massachusetts , Connecticut ... flu shots through the end of the month. *Some exclusions ... ... shot is by the end of October, according to the Centers for ...
Breaking Medicine Technology: